{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:00:40Z","timestamp":1789012840558,"version":"build-2803163510"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,11,7]]},"abstract":"<jats:p>This JAMA Clinical Guidelines Synopsis summarizes the American Association of Clinical Endocrinology\u2019s 2022 clinical practice guideline for diagnosis and management of nonalcoholic fatty liver disease.<\/jats:p>","DOI":"10.1001\/jama.2023.17935","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T15:31:53Z","timestamp":1697470313000},"page":"1687","source":"Crossref","is-referenced-by-count":47,"title":["Diagnosis and Management of Nonalcoholic Fatty Liver Disease"],"prefix":"10.1001","volume":"330","author":[{"given":"Peggy B.","family":"Leung","sequence":"first","affiliation":[{"name":"Division of General Internal Medicine, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Davis","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, NewYork-Presbyterian Hospital\/Weill Cornell Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"jgs230007r1","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1016\/j.cgh.2021.12.015","article-title":"Prevalence of high and moderate risk nonalcoholic fatty liver disease among adults in the United States, 1999-2016.","volume":"20","author":"Golabi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"jgs230007r2","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings.","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"2","key":"jgs230007r3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/liv.v41.2","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events.","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int"},{"issue":"12","key":"jgs230007r4","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1016\/j.cgh.2019.03.006","article-title":"Optimizing use of nonalcoholic fatty liver disease fibrosis score, Fibrosis-4 Score, and liver stiffness measurement to identify patients with advanced fibrosis.","volume":"17","author":"Chan","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"jgs230007r5","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events.","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"jgs230007r6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cld.2023.01.002","article-title":"Metabolic syndrome and its association with nonalcoholic steatohepatitis.","volume":"27","author":"Bril","year":"2023","journal-title":"Clin Liver Dis"},{"issue":"12","key":"jgs230007r7","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis.","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"jgs230007r8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis.","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"5","key":"jgs230007r9","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease.","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"jgs230007r10","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature.","author":"Rinella","year":"2023","journal-title":"J Hepatol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2810964\/jama_leung_2023_gs_230007_1698789129.40345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T16:38:46Z","timestamp":1699375126000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2810964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":10,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,11,7]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.17935","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,7]]}}}